Supplementary material

| SUPPLEMENT 1. CIDI-SF LIFETIME DEPRESSION CRITERIA | 2 |
|--|----|
| SUPPLEMENT 2. ICD-10 CODES FOR DEPRESSION | |
| SUPPLEMENT 3. SMITH ET AL. DEPRESSION CRITERIA | |
| SUPPLEMENT 4. PSYCHOTROPIC MEDICATION CODES | |
| SUPPLEMENT 5. ANTIHYPERTENSIVE MEDICATION CODES | |
| SUPPLEMENT 6. SAMPLE CHARACTERISTICS | 8 |
| SUPPLEMENT 7. ADJUSTED GAMS | |
| 7A. AGE-RELATED CHANGES IN FEMALES | |
| 7B. AGE-RELATED CHANGES IN MALES | |
| SUPPLEMENT 8. SENSITIVITY ANALYSES | |
| 8A. CASE-CONTROL NUMBERS | 13 |
| 8B. CASE CONTROL DIFFERENCES | 14 |
| 8C. AGE-RELATED CHANGES IN FEMALES. | |
| 8D. AGE-RELATED CHANGES IN MALES | 17 |

Supplement 1. CIDI-SF lifetime depression criteria

Supplement table 1. Case definition lifetime depression

Lifetime depression (case):

At least one core symptom of major depressive disorder, most or all of the day on most or all days for a two-week period, with at least five non-core depressive symptoms that represent a change from usual occurring over the same timescale, with some or a lot of impairment.

No record of psychosis or bipolar disorder.

Definition and UK Biobank data fields

("Ever had prolonged feelings of sadness or depression" (20446) = Yes OR "Ever had prolonged loss of interest in normal activities" (20441) = Yes)

AND

"Fraction of day affected during worst episode of depression" (20436) = Most of day or All day long AND

"Frequency of depressed days during worst episode of depression" (20439) = "Almost every day" or "Every day" AND "Impact on normal roles during worst period of depression" (20440) = "Somewhat" or "A lot" AND

Total number of symptoms endorsed (core and others) ≥5: "Ever had prolonged feelings of sadness or depression" (core) (20446), "Ever had prolonged loss of interest in normal activities" (core) (20441), "Feelings of tiredness during worst episode of depression" (20449), "Weight change during worst episode of depression" (20532), "Did your sleep change?" (20532), "Difficulty concentrating during worst depression (20435), "Feelings of worthlessness during worst period of depression" (20450), "Thoughts of death during worst depression" (20437)

AND

No self-reported psychosis or mania for "Mental health problems ever diagnosed by a professional" (20544) AND

No self-reported mania/bipolar disorder/manic depression or schizophrenia for "Non-cancer illness" (20002) AND

No ICD-10 code for "manic episode" or "bipolar affective disorder" (F30-F31) or "schizophrenia, schizotypal and delusional disorders" (F20-F29)

No probable bipolar disorder (20126) according to Smith et al. (2013)

AND

 ${f No}$ bipolar disorder record according to the MHQ AND

No primary care record of bipolar disorder or psychosis

Note: Criteria for lifetime depression adapted from Davis et al. (2020), doi: 10.1192/bjo.2019.100. CIDI-SF = Composite International Diagnostic Interview Short Form; ICD-10 = International Classification of Diseases, Tenth Revision; MHQ = mental health questionnaire.

Supplement 2. ICD-10 codes for depression

Depressive episode

- F32.0 Mild depressive episode
- F32.1 Moderate depressive episode
- F32.2 Severe depressive episode without psychotic symptoms
- F32.3 Severe depressive episode with psychotic symptoms
- F32.8 Other depressive episodes
- F32.9 Depressive episode, unspecified

Recurrent depressive disorder

- F33.0 Recurrent depressive disorder, current episode mild
- F33.1 Recurrent depressive disorder, current episode moderate
- F33.2 Recurrent depressive disorder, current episode severe without psychotic symptoms
- F33.3 Recurrent depressive disorder, current episode severe with psychotic symptoms
- F33.4 Recurrent depressive disorder, currently in remission
- F33.8 Other recurrent depressive disorders
- F33.9 Recurrent depressive disorder, unspecified

Supplement 3. Smith et al. depression criteria

Depression (adapted from Smith et al. (2013), doi: 10.1371/journal.pone.0075362).

3. Single probable episode of major depression:

 $\underline{4598}$ ever depressed/down for a whole week; plus $\underline{4609}$ at least two weeks duration; plus

 $\frac{4620}{OR}$ only one episode, plus $\frac{2090}{OR}$ ever seen a GP or $\frac{2100}{OR}$ a psychiatrist for nerves, anxiety, depression OR

4631 ever anhedonic (unenthusiasm/uninterest) for a whole week; plus 5375 at least two weeks; plus

5386 only one episode; plus 2090 ever seen a GP or 2100 a psychiatrist for nerves, anxiety, depression.

4. Probable recurrent major depression (moderate):

 $\frac{4598}{2090}$ ever depressed/down for a whole week; plus $\frac{4609}{2090}$ at least two weeks duration; plus $\frac{4620}{2090}$ at least two episodes; plus $\frac{2090}{2090}$ ever seen a GP (but not a psychiatrist) for nerves, anxiety, depression

4631 ever anhedonic (unenthusiasm/uninterest) for a whole week; plus 5375 at least two weeks; plus

5386 at least two episodes; plus 2090 ever seen a GP (but not a psychiatrist) for nerves, anxiety, depression.

5. Probable recurrent major depression (severe):

4598 ever depressed/down for a whole week; plus 4609 at least two weeks duration; plus 4620 at least two episodes; plus 2100 ever seen a psychiatrist for nerves, anxiety, depression OR

4631 ever anhedonic (unenthusiasm/uninterest) for a whole week; plus 5375 at least two weeks; plus

5386 at least two episodes; plus 2100 ever seen a psychiatrist for nerves, anxiety, depression.

Supplement 4. Psychotropic medication codes

Supplement table 2. Psychotropic medication codes

| Supplement table 2 | . Psychotropic medication codes |
|--------------------------|--|
| UK Biobank code | Drug name |
| 1140879616 | Amitriptyline |
| 1140921600 | Citalopram |
| 1140879540 | Fluoxetine |
| 1140867878 | Sertraline |
| 1140916282 | Venlafaxine |
| 1140909806 | Dosulepin |
| 1140867888 | Paroxetine |
| 1141152732 | Mirtazapine |
| 1141180212 | Escitalopram |
| 1140879634 | Trazodone |
| 1140867876 | Prozac |
| 1140882236 | Seroxat |
| 1141190158 | Cipralex |
| 1141200564 | Duloxetine |
| 1140867726 | Lofepramine |
| 1140879620 | Clomipramine |
| 1140867818 | Nortriptyline |
| 1140879630 | Imipramine |
| 1140879628 | Dothiepin |
| 1141151946 | Cipramil |
| 1140867948 | Amitriptyline |
| 1140867624 | Prothiaden |
| 1140867756 | Trimipramine |
| 1140867884 | Lustral |
| 1141151978 | Reboxetine |
| 1141152736 | Zispin |
| 1141201834 | Cymbalta |
| 1140867690 | Anafranil |
| 1140867640 | Doxepin |
| 1140867920 | Moclobemide |
| 1140867850 | Phenelzine |
| 1140879544 | Fluvoxamine |
| 1141200570 | Yentreve |
| 1140867934 | Triptafen |
| 1140867758 | Surmontil |
| 1140867914 | Tranyleypromine |
| 1140867820 | Allegron |
| 1141151982 1140882244 | Edronax Molipaxin |
| 1140879556 | Mianserin |
| 1140867852 | Nardil |
| 1140867860 | Faverin |
| 1140917460 | Nefazodone |
| 1140867938 | Amitriptyline+Chlordiazepoxide |
| 1140867856 | Isocarboxazid |
| 1140867922 | Manerix |
| 1140910820 | Maoi |
| 1140882312 | Sinequan |
| 1140867944 | Tranylcypromine+Trifluoperazine |
| 1140867784 | Ludiomil |
| 1140867812 | Norval |
| 1140867668 | Tryptizol |
| 1140867940* | Fluphenazine hydrochloride+Nortriptyline 1.5mg/30mg tablet |
| 1140867942* | Fluphenazine hcl+Nortriptyline 500micrograms/10mg tablet |
| 1140928916 | Olanzapine |
| 1141152848 | Quetiapine |
| 1140867444 | Risperidone |
| 1140879658 | Chlorpromazine |
| 1140868120 | Trifluoperazine |
| 1141153490 | Amisulpride |
| 1140867304 | Sulpiride |
| 1141152860 | Seroquel |
| 1140867168 | Haloperidol |
| 1141195974 | Aripiprazole |
| 1140867244 | Stelazine |
| 1140867152 | Depixol |
| 1140909800 | Flupentixol |
| 1140867420 | Clozapine |
| 1140879746 | Promazine |
| 1141177762 | Risperdal |
| 1140867456 | Modecate |
| 1140867952 | Fluanxol |
| 1140867150 | Flupenthixol |
| 1141167976 | Zyprexa |
| | |

| 1140882100 | Zuclopenthixol |
|------------|-------------------------------------|
| 1140867342 | Clopixol |
| 1140863416 | Largactil |
| 1141202024 | Abilify |
| 1140882098 | Fluphenazine |
| 1140867184 | Haldol |
| 1140867092 | Serenace |
| 1140882320 | Clozaril |
| 1140910358 | Cpz |
| 1140867208 | Perphenazine |
| 1140909802 | Levomepromazine |
| 1140867134 | Pericyazine |
| 1140867306 | Dolmatil |
| 1140867210 | Fentazin |
| 1140867398 | Fluphenazine |
| 1140867078 | Benperidol |
| 1140867218 | Pimozide |
| 1141201792 | Zaponex |
| 1141200458 | Denzapine |
| 1140867136 | Neulactil |
| 1140879750 | Thioridazine |
| 1140867180 | Dozic |
| 1140867546 | Fluspirilene |
| 1140928260 | Panadeine |
| 1140927956 | Sertindole |
| 1140867490 | Lithium product |
| 1140867494 | Camcolit 250 tablet |
| 1140867498 | Liskonum 450mg m/r tablet |
| 1140867500 | Phasal 300mg m/r tablet |
| 1140867504 | Priadel 200mg m/r tablet |
| 1140867518 | Litarex 564mg m/r tablet |
| 1140867520 | Li-liquid 5.4mmol/5ml oral solution |

Note: Adapted from Davis et al. (2019), doi: 10.1002/mpr.1796. *medication code not included in Davis et al. (2019).

Supplement 5. Antihypertensive medication codes

Supplement table 3. Antihypertensive medication codes

| Supplement table 3. Antihypertensive medication codes | | | | | | |
|---|-----------------------------|--|--|--|--|--|
| UK Biobank code | Drug name | | | | | |
| 1140861848 | Colestid 5g/sachet granules | | | | | |
| 1140861922 | Lipid lowering drug | | | | | |
| 1140861924 | Bezafibrate | | | | | |
| 1140861926 | Bezalip 200mg tablet | | | | | |
| 1140861936 | Questran 4g/sachet powder | | | | | |
| 1140861944 | Clofibrate | | | | | |
| 1140861954 | Fenofibrate | | | | | |
| 1140861958 | Simvastatin | | | | | |
| 1140861970 | Lipostat 10mg tablet | | | | | |
| 1140862026 | Ciprofibrate | | | | | |
| 1140864592 | Lescol 20mg capsule | | | | | |
| 1140881748 | Zocor 10mg tablet | | | | | |
| 1140888590 | Colestipol | | | | | |
| 1140888594 | Fluvastatin | | | | | |
| 1140888648 | Pravastatin | | | | | |
| 1140909780 | Colestyramine | | | | | |
| 1141146138 | Lipitor 10mg tablet | | | | | |
| 1141146234 | Atorvastatin | | | | | |
| 1141157260 | Bezafibrate product | | | | | |
| 1141162544 | Lipantil micro 67mg capsule | | | | | |
| 1141172214 | Supralip 160mg m/r tablet | | | | | |
| 1141180734 | Colestyramine product | | | | | |
| 1141188146 | Simvador 10mg tablet | | | | | |
| 1141192410 | Rosuvastatin | | | | | |
| 1141192414 | Crestor 10mg tablet | | | | | |
| 1141192736 | Ezetimibe | | | | | |
| 1141192740 | Ezetrol 10mg tablet | | | | | |
| 1141195196 | Ranzolont 10mg tablet | | | | | |
| 1141200040 | Zocor heart-pro 10mg tablet | | | | | |

Supplement 6. Sample characteristics


Supplement table 4. Sample characteristics

| | Overall | Healthy control | nale Depression | Ma Healthy control | Depression |
|--------------------------------|-----------------|-----------------|-----------------|-----------------------|------------------|
| | (N=502521) | (N=123842) | (N=56276) | (N=131212) | (N=31063) |
| Age | (14 302321) | (11 123042) | (11 30270) | (11 131212) | (17 31003) |
| Mean (SD) | 56.53 (8.10) | 55.90 (8.03) | 54.74 (7.78) | 56.37 (8.26) | 55.71 (7.96) |
| Ethnicity | ` ' | ` / | ` ' | , , | . , |
| White | 472711 (94.1%) | 117587 (94.9%) | 54386 (96.6%) | 125053 (95.3%) | 30089 (96.9%) |
| Mixed-race | 2958 (0.6%) | 805 (0.7%) | 434 (0.8%) | 588 (0.4%) | 145 (0.5%) |
| Asian | 8061 (1.6%) | 2096 (1.7%) | 556 (1.0%) | 1779 (1.4%) | 195 (0.6%) |
| Black | 9882 (2.0%) | 1809 (1.5%) | 459 (0.8%) | 2518 (1.9%) | 393 (1.3%) |
| Chinese | 1574 (0.3%) | 527 (0.4%) | 91 (0.2%) | 357 (0.3%) | 37 (0.1%) |
| Other | 4558 (0.9%) | 1018 (0.8%) | 350 (0.6%) | 917 (0.7%) | 204 (0.7%) |
| Prefer not to answer | 1662 (0.3%) | () | , | () | . () |
| Do not know | 217 (<0.1%) | | | | |
| Missing | 898 (0.2%) | | | | |
| Household income ¹ | , | | | | |
| Very low | 97205 (19.3%) | 26243 (21.2%) | 13986 (24.9%) | 21903 (16.7%) | 7181 (23.1%) |
| Low | 108177 (21.5%) | 32464 (26.2%) | 14751 (26.2%) | 31452 (24.0%) | 7472 (24.1%) |
| Middle | 110774 (22.0%) | 32735 (26.4%) | 14575 (25.9%) | 36631 (27.9%) | 8233 (26.5%) |
| High | 86269 (17.2%) | 25352 (20.5%) | 10605 (18.8%) | 31999 (24.4%) | 6599 (21.2%) |
| Very high | 22930 (4.6%) | 7048 (5.7%) | 2359 (4.2%) | 9227 (7.0%) | 1578 (5.1%) |
| Prefer not to answer | 49848 (9.9%) | 7010 (3.770) | 2337 (4.270) | 7227 (1.070) | 15 / 5 (5.1 / 6) |
| Do not know | 21305 (4.2%) | | | | |
| Missing | 6013 (1.2%) | | | | |
| Walking ² | 0013 (1.270) | | | | |
| Mean (SD) | 5.39 (1.93) | 5.48 (1.84) | 5.35 (1.95) | 5.31 (1.99) | 5.23 (2.06) |
| Prefer not to answer | 979 (0.2%) | 3.40 (1.04) | 3.33 (1.73) | 3.31 (1.77) | 3.23 (2.00) |
| Unable to walk | 1929 (0.4%) | | | | |
| Do not know | 6687 (1.3%) | | | | |
| Missing | 874 (0.2%) | | | | |
| Moderate activity ² | 074 (0.270) | | | | |
| Mean (SD) | 3.63 (2.33) | 3.62 (2.31) | 3.51 (2.34) | 3.59 (2.31) | 3.46 (2.35) |
| Prefer not to answer | 2273 (0.5%) | 3.02 (2.31) | 3.31 (2.34) | 3.37 (2.31) | 3.40 (2.33) |
| Do not know | 24120 (4.8%) | | | | |
| Missing | 878 (0.2%) | | | | |
| Vigorous activity ² | 878 (0.270) | | | | |
| Mean (SD) | 1.84 (1.96) | 1.73 (1.85) | 1.61 (1.82) | 2.10 (2.02) | 1.95 (2.02) |
| Prefer not to answer | , , | 1.73 (1.63) | 1.01 (1.62) | 2.10 (2.02) | 1.93 (2.02) |
| Do not know | 4116 (0.8%) | | | | |
| | 22582 (4.5%) | | | | |
| Missing | 878 (0.2%) | | | | |
| Smoking status | 272520 (54.40/) | 770(0 ((2 20/) | 20207 (52 00/) | (7027 (51.90/) | 12050 (44.00/) |
| Never | 273528 (54.4%) | 77069 (62.2%) | 30307 (53.9%) | 67927 (51.8%) | 13959 (44.9%) |
| Former | 173064 (34.4%) | 37682 (30.4%) | 19633 (34.9%) | 49044 (37.4%) | 12473 (40.2%) |
| Current | 52979 (10.5%) | 9091 (7.3%) | 6336 (11.3%) | 14241 (10.9%) | 4631 (14.9%) |
| Prefer not to answer | 2059 (0.4%) | | | | |
| Missing | 891 (0.2%) | | | | |
| Alcohol intake frequency | 40645 (0.10/) | 0017 (7.40/) | 4650 (0.20() | (200 (4 00/) | 2222 (7 50/) |
| Never | 40645 (8.1%) | 9217 (7.4%) | 4658 (8.3%) | 6290 (4.8%) | 2323 (7.5%) |
| Special occasions | 58011 (11.5%) | 16310 (13.2%) | 8361 (14.9%) | 8259 (6.3%) | 2436 (7.8%) |
| 1-3/month | 55856 (11.1%) | 15862 (12.8%) | 7869 (14.0%) | 11184 (8.5%) | 3054 (9.8%) |
| 1-2/week | 129294 (25.7%) | 33072 (26.7%) | 14017 (24.9%) | 34139 (26.0%) | 7516 (24.2%) |
| 3-4/week | 115443 (23.0%) | 28093 (22.7%) | 11628 (20.7%) | 36606 (27.9%) | 7587 (24.4%) |
| Daily/almost daily | 101770 (20.3%) | 21288 (17.2%) | 9743 (17.3%) | 34734 (26.5%) | 8147 (26.2%) |
| Prefer not to answer | 605 (0.1%) | | | | |
| Missing | 897 (0.2%) | | | | |
| Sleep duration | | | | | |
| Mean (SD) | 7.15 (1.11) | 7.18 (1.00) | 7.17 (1.17) | 7.13 (0.99) | 7.11 (1.21) |
| Prefer not to answer | 386 (0.1%) | | | | |
| Do not know | 2943 (0.6%) | | | | |
| Missing | 887 (0.2%) | | | | |


Note: Descriptive statistics for covariates based on main dataset N=342,393. ¹Annual household income groups: very low (\leq £18 000), low (£18 000-30 999), middle (£31 000-51 999), high (£52 000-100 000) and very high (\geq £100 000). ²number of days per week engaging in these activities for 10+ minutes continuously.

Supplement 7. Adjusted GAMs

7A. Age-related changes in females




Supplement figure 1. Adjusted generalised additive models of age-related changes in physiological measures in females with lifetime depression and healthy controls. Models were adjusted for ethnicity (except lung function), gross annual household income, physical activity, smoking status, alcohol intake frequency, sleep duration and, for cardiovascular measures, current use of antihypertensive medications. The solid lines represent physiological measures against smoothing functions of age. The shaded areas correspond to approximate 95% confidence intervals (\pm 2 × standard error). FEV₁ = forced expiratory volume in one second; FVC = forced vital capacity.




Supplement figure 2. Difference smooths comparing age-related changes in physiological measures of females with lifetime depression to healthy controls. Models were adjusted for ethnicity (except lung function), gross annual household income, physical activity, smoking status, alcohol intake frequency, sleep duration and, for cardiovascular measures, current use of antihypertensive medications. The shaded areas correspond to approximate 95% confidence intervals ($\pm 2 \times$ standard error). Negative values on the y-axes correspond to lower values in females with lifetime depression compared to healthy controls. The horizontal lines represent no difference between female cases and controls. FEV₁ = forced expiratory volume in one second; FVC = forced vital capacity; Bonf. = Bonferroni; BH = Benjamini & Hochberg.

7B. Age-related changes in males



Supplement figure 3. Adjusted generalised additive models of age-related changes in physiological measures in males with lifetime depression and healthy controls. Models were adjusted for ethnicity (except lung function), gross annual household income, physical activity, smoking status, alcohol intake frequency, sleep duration and, for cardiovascular measures, current use of antihypertensive medications. The solid lines represent physiological measures against smoothing functions of age. The shaded areas correspond to approximate 95% confidence intervals (\pm 2 × standard error). FEV₁ = forced expiratory volume in one second; FVC = forced vital capacity.



Supplement figure 4. Difference smooths comparing age-related changes in physiological measures of males with lifetime depression to healthy controls. Models were adjusted for ethnicity (except lung function), gross annual household income, physical activity, smoking status, alcohol intake frequency, sleep duration and, for cardiovascular measures, current use of antihypertensive medications. The shaded areas correspond to approximate 95% confidence intervals (\pm 2 × standard error). Negative values on the y-axes correspond to lower values in males with lifetime depression compared to healthy controls. The horizontal lines represent no difference between male cases and controls. FEV₁ = forced expiratory volume in one second; FVC = forced vital capacity; Bonf. = Bonferroni; BH = Benjamini & Hochberg.

Supplement 8. Sensitivity analyses

8A. Case-control numbers

Supplement table 5. Case-control numbers sensitivity analyses

| Dataset | | ≥ 2 depressio | n measures | CIDI-SF lifetime depression (MHQ) | | |
|----------------------|--------|-----------------|------------|-----------------------------------|------------|--|
| | Sex | Healthy control | Depression | Healthy control | Depression | |
| Main dataset | Female | 123842 | 23517 | 30113 | 20482 | |
| | Male | 131212 | 11785 | 32776 | 9432 | |
| Lung function | Female | 43133 | 8010 | 10750 | 7162 | |
| | Male | 52359 | 4617 | 13586 | 3826 | |
| Bone mineral density | Female | 85994 | 12219 | 19420 | 12907 | |
| | Male | 89790 | 6075 | 21289 | 6005 | |
| Arterial stiffness | Female | 38592 | 11525 | 10818 | 7688 | |
| | Male | 42889 | 5899 | 11805 | 3528 | |

Note: CIDI-SF = Composite International Diagnostic Interview Short Form; MHQ = mental health questionnaire.


8B. Case control differences

Supplement table 6. Differences in physiological measures between individuals with lifetime depression and healthy controls


| | ≥ 2 depression measures | | | | CIDI-SF lifetime depression (MHQ) | | | | | |
|-----------------------------|------------------------------|--------|--------|----------------------|-----------------------------------|--------|--------|--------|----------------------|-------------------|
| Variable | SMD | 95% | 6 CI | $p_{\mathrm{Bonf.}}$ | p_{BH} | SMD | 95% CI | | $p_{\mathrm{Bonf.}}$ | p_{BH} |
| Female | | | | | | | | | | |
| Hand-grip strength | -0.067 | -0.081 | -0.053 | < 0.001 | < 0.001 | -0.042 | -0.060 | -0.025 | < 0.001 | < 0.001 |
| Systolic blood pressure | -0.192 | -0.206 | -0.178 | < 0.001 | < 0.001 | -0.162 | -0.180 | -0.145 | < 0.001 | < 0.001 |
| Diastolic blood pressure | -0.047 | -0.061 | -0.033 | < 0.001 | < 0.001 | -0.005 | -0.023 | 0.013 | >0.999 | 0.600 |
| Pulse rate | 0.028 | 0.014 | 0.042 | 0.002 | < 0.001 | 0.052 | 0.034 | 0.070 | < 0.001 | < 0.001 |
| Body mass index | 0.190 | 0.176 | 0.204 | < 0.001 | < 0.001 | 0.230 | 0.212 | 0.248 | < 0.001 | < 0.001 |
| Body fat percentage | 0.165 | 0.151 | 0.179 | < 0.001 | < 0.001 | 0.193 | 0.175 | 0.210 | < 0.001 | < 0.001 |
| Fat mass | 0.211 | 0.197 | 0.225 | < 0.001 | < 0.001 | 0.227 | 0.209 | 0.245 | < 0.001 | < 0.001 |
| Fat-free mass | 0.181 | 0.167 | 0.195 | < 0.001 | < 0.001 | 0.166 | 0.148 | 0.184 | < 0.001 | < 0.001 |
| Waist-hip ratio | 0.115 | 0.101 | 0.129 | < 0.001 | < 0.001 | 0.122 | 0.104 | 0.139 | < 0.001 | < 0.001 |
| Peak expiratory flow | 0.120 | 0.096 | 0.144 | < 0.001 | < 0.001 | 0.073 | 0.043 | 0.103 | < 0.001 | < 0.001 |
| Forced expiratory volume 1s | 0.110 | 0.086 | 0.134 | < 0.001 | < 0.001 | 0.067 | 0.037 | 0.097 | < 0.001 | < 0.001 |
| Forced vital capacity | 0.102 | 0.078 | 0.126 | < 0.001 | < 0.001 | 0.049 | 0.019 | 0.079 | 0.021 | 0.002 |
| FEV ₁ / FVC | 0.043 | 0.019 | 0.067 | 0.006 | < 0.001 | 0.051 | 0.021 | 0.081 | 0.011 | 0.001 |
| Heel bone mineral density | 0.024 | 0.005 | 0.043 | 0.177 | 0.013 | 0.028 | 0.005 | 0.050 | 0.227 | 0.017 |
| Arterial stiffness | 0.007 | -0.014 | 0.028 | >0.999 | 0.448 | 0.016 | -0.013 | 0.045 | >0.999 | 0.301 |
| Male | | | | | | | | | | |
| Hand-grip strength | -0.116 | -0.135 | -0.097 | < 0.001 | < 0.001 | -0.002 | -0.025 | 0.020 | >0.999 | 0.900 |
| Systolic blood pressure | -0.159 | -0.178 | -0.140 | < 0.001 | < 0.001 | -0.143 | -0.166 | -0.120 | < 0.001 | < 0.001 |
| Diastolic blood pressure | -0.044 | -0.063 | -0.025 | < 0.001 | < 0.001 | -0.002 | -0.025 | 0.021 | >0.999 | 0.900 |
| Pulse rate | 0.109 | 0.090 | 0.128 | < 0.001 | < 0.001 | 0.088 | 0.066 | 0.111 | < 0.001 | < 0.001 |
| Body mass index | 0.140 | 0.121 | 0.158 | < 0.001 | < 0.001 | 0.192 | 0.169 | 0.215 | < 0.001 | < 0.001 |
| Body fat percentage | 0.134 | 0.115 | 0.153 | < 0.001 | < 0.001 | 0.142 | 0.119 | 0.165 | < 0.001 | < 0.001 |
| Fat mass | 0.165 | 0.146 | 0.184 | < 0.001 | < 0.001 | 0.183 | 0.160 | 0.206 | < 0.001 | < 0.001 |
| Fat-free mass | 0.097 | 0.078 | 0.116 | < 0.001 | < 0.001 | 0.137 | 0.114 | 0.160 | < 0.001 | < 0.001 |
| Waist-hip ratio | 0.167 | 0.148 | 0.185 | < 0.001 | < 0.001 | 0.167 | 0.144 | 0.190 | < 0.001 | < 0.001 |
| Peak expiratory flow | 0.005 | -0.025 | 0.035 | >0.999 | 0.793 | 0.019 | -0.017 | 0.055 | >0.999 | 0.413 |
| Forced expiratory volume 1s | 0.003 | -0.027 | 0.033 | >0.999 | 0.837 | 0.045 | 0.009 | 0.081 | 0.224 | 0.022 |
| Forced vital capacity | 0.011 | -0.019 | 0.041 | >0.999 | 0.564 | 0.046 | 0.011 | 0.082 | 0.190 | 0.021 |
| FEV ₁ / FVC | -0.013 | -0.043 | 0.017 | >0.999 | 0.517 | 0.006 | -0.030 | 0.042 | >0.999 | 0.900 |
| Heel bone mineral density | -0.101 | -0.127 | -0.075 | < 0.001 | < 0.001 | -0.074 | -0.102 | -0.045 | < 0.001 | < 0.001 |
| Arterial stiffness | 0.020 | -0.007 | 0.047 | >0.999 | 0.092 | 0.001 | -0.037 | 0.038 | >0.999 | 0.974 |

Note: SMD = standardised mean difference; CI = confidence interval; Bonf. = Bonferroni; BH = Benjamini & Hochberg; FEV_1 = forced expiratory volume in one second; FVC = forced vital capacity; CIDI-SF = Composite International Diagnostic Interview Short Form; MHQ = mental health questionnaire. P-values for Welch's t-test.

8C. Age-related changes in females




Supplement figure 5. Difference smooths comparing age-related changes in physiological measures of females with lifetime depression (\geq 2 depression measures) to healthy controls. Models were adjusted for ethnicity (except lung function), gross annual household income, physical activity, smoking status, alcohol intake frequency, sleep duration and, for cardiovascular measures, current use of antihypertensive medications. The shaded areas correspond to approximate 95% confidence intervals (\pm 2 × standard error). Negative values on the y-axes correspond to lower values in females with lifetime depression compared to healthy controls. The horizontal lines represent no difference between female cases and controls. FEV₁ = forced expiratory volume in one second; FVC = forced vital capacity; Bonf. = Bonferroni; BH = Benjamini & Hochberg.




Supplement figure 6. Difference smooths comparing age-related changes in physiological measures of females with lifetime depression (CIDI-SF) to healthy controls. Models were adjusted for ethnicity (except lung function), gross annual household income, physical activity, smoking status, alcohol intake frequency, sleep duration and, for cardiovascular measures, current use of antihypertensive medications. The shaded areas correspond to approximate 95% confidence intervals (\pm 2 × standard error). Negative values on the y-axes correspond to lower values in females with lifetime depression compared to healthy controls. The horizontal lines represent no difference between female cases and controls. FEV₁ = forced expiratory volume in one second; FVC = forced vital capacity; Bonf. = Bonferroni; BH = Benjamini & Hochberg.

8D. Age-related changes in males



Supplement figure 7. Difference smooths comparing age-related changes in physiological measures of males with lifetime depression (\geq 2 depression measures) to healthy controls. Models were adjusted for ethnicity (except lung function), gross annual household income, physical activity, smoking status, alcohol intake frequency, sleep duration and, for cardiovascular measures, current use of antihypertensive medications. The shaded areas correspond to approximate 95% confidence intervals (\pm 2 × standard error). Negative values on the y-axes correspond to lower values in males with lifetime depression compared to healthy controls. The horizontal lines represent no difference between male cases and controls. FEV₁ = forced expiratory volume in one second; FVC = forced vital capacity; Bonf. = Bonferroni; BH = Benjamini & Hochberg.



Supplement figure 8. Difference smooths comparing age-related changes in physiological measures of males with lifetime depression (CIDI-SF) to healthy controls. Models were adjusted for ethnicity (except lung function), gross annual household income, physical activity, smoking status, alcohol intake frequency, sleep duration and, for cardiovascular measures, current use of antihypertensive medications. The shaded areas correspond to approximate 95% confidence intervals (\pm 2 × standard error). Negative values on the y-axes correspond to lower values in males with lifetime depression compared to healthy controls. The horizontal lines represent no difference between male cases and controls. FEV₁ = forced expiratory volume in one second; FVC = forced vital capacity; Bonf. = Bonferroni; BH = Benjamini & Hochberg.